Functional efficacy of glatiramer acetate treatment for laser-induced retinal damage in rats

Lasers in Surgery and Medicine

Volumn 40, Issue 3, 2008, Pages 196-201

  Belokopytov, Mark ^a   Ben Shlomo, Gil ^b   Rosner, Mordechai ^a   Belkin, Michael ^a,c   Dubinski, Galina ^a   Epstein, Yoram ^a   Ofri, Ron ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

Author keywords

Electroretinogram; Laser; Neuroprotection; Retinal injury; Wound healing

Indexed keywords

GLATIRAMER; PLACEBO;

AMPLITUDE MODULATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARGON LASER; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ELECTRORETINOGRAPHY; IMMUNIZATION; LASER; LASER COAGULATION; MALE; MYELINATION; NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RAT; RETINA INJURY; STANDARD; TREATMENT OUTCOME; TREATMENT RESPONSE; WOUND HEALING;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ELECTRORETINOGRAPHY; EYE BURNS; LASER COAGULATION; MALE; PEPTIDES; PREMEDICATION; RATS; RETINA;

EID: 41849109188     PISSN: 01968092     EISSN: 10969101     Source Type: Journal    
DOI: 10.1002/lsm.20610     Document Type: Article

References (51)

1. Yoles E, Schwartz M. Degeneration of spared axons following partial white matter lesion: Implications for optic nerve neuropathies. Exp Neuro 1998;153:1-7.
2. Crowe MJ, Bresnahan JC, Shuman SL, Masters JN, Beattie MS. Apoptosis and delayed degeneration after spinal cord injury in rats and monkeys. Nat Med 1997;3:73-76.
3. Lynch DR, Dawson TM. Secondary mechanisms in neuronal trauma. Curr Opin Neurol 1994;7:510-516.
4. Attwell D, Barbour B, Szatkowski M. Nonvesicular release of neurotransmitter. Neuron 1993;11:401-407.
5. Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988;1:623-634.
6. Dkhissi O, Chanut E, Wasowicz M, Savoldelli M, Nguyen-Legros J, Minvielle F, Versaux-Botteri C. Retinal TUNEL-positive cells and high glutamate levels in vitreous humor of mutant quail with a glaucoma-like disorder. Invest Ophthalmol Vis Sci 1999;40:990-995.
7. Osborne NN, Ugarte M, Chao M, Chidlow G, Bae JH, Wood JP, Nash MS. Neuroprotection in relation to retinal ischemia and relevance to glaucoma. Surv Ophthalmol 1999;43:S102-S128.
8. Barkana Y, Belkin M. Neuroprotection in ophthalmology: A review. Brain Res Bull 2004;62:447-453.
9. Osborne NN, Chidlow G, Wood JP, Schmidt KG, Casson R, Melena J. Expectations in the treatment of retinal diseases: Neuroprotection. Curr Eye Res 2001;22:321-332.
10. Solberg Y, Rosner M, Turetz J, Belkin M. MK-801 has neuroprotective and antiproliferative effects in retinal laser injury. Invest Ophthalmol Vis Sci 1997;38:1380-1389.
11. Chidlow G, Osborne NN. Rat retinal ganglion cell loss caused by kainate, NMDA and ischemia correlates with a reduction in mRNA and protein of Thy-1 and neurofilament light. Brain Res 2003;963:298-306.
12. Hauben E, Butovsky O, Nevo U, Yoles E, Moalem G, Agranov E, Mor F, Leibowitz-Amit R, Pevsner E, Akselrod S, Neeman M, Cohen IR, Schwartz M. Passive or active immunization with myelin basic protein promotes recovery from spinal cord contusion. J Neurosci 2000;20:6421-6430.
13. Kipnis J, Yoles E, Schori H, Hauben E, Shaked I, Schwartz M. Neuronal survival after CNS insult is determined by a genetically encoded autoimmune response. J Neurosci 2001;21:4564-4571.
14. Mizrahi T, Hauben E, Schwartz M. The tissue-specific self-pathogen is the protective self-antigen: The case of uveitis. J Immunol 2002;169:5971-5977.
15. Schori H, Kipnis J, Yoles E, WoldeMussie E, Ruiz G, Wheeler LA, Schwartz M. Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: Implications for glaucoma. Proc Natl Acad Sci USA 2001;98:3398-3403.
16. Yoles E, Hauben E, Palgi O, Agranov E, Gothilf A, Cohen A, Kuchroo V, Cohen IR, Weiner H, Schwartz M. Protective autoimmunity is a physiological response to CNS trauma. J Neurosci 2001;21:3740-3748.
17. Muhallab S, Lundberg C, Gielen AW, Lidman O, Svenningsson A, Piehl F, Olsson T. Differential expression of neurotrophic factors and inflammatory cytokines by myelin basic protein-specific and other recruited T cells infiltrating the central nervous system during experimental autoimmune encephalomyelitis. Scand J Immunol 2002;55:264-273.
18. Hammarberg H, Lidman O, Lundberg C, Eltayeb SY, Gielen AW, Muhallab S, Svenningsson A, Linda H, van Der Meide PH, Cullheim S, Olsson T, Piehl F. Neuroprotection by encephalomyelitis: Rescue of mechanically injured neurons and neurotrophin production by CNS-infiltrating T and natural killer cells. J Neurosci 2000;20:5283-5291.
19. Bakalash S, Kessler A, Mizrahi T, Nussenblatt R, Schwartz M. Antigenic specificity of immunoprotective therapeutic vaccination for glaucoma. Invest Ophthalmol Vis Sci 2003;44:3374-3381.
20. Butovsky O, Hauben E, Schwartz M. Morphological aspects of spinal cord autoimmune neuroprotection: Colocalization of T cells with B 7-2(CD86) and prevention of cyst formation. FASEB J 2001;15:1065-1067.
21. Bakalash S, Kipnis J, Yoles E, Schwartz M. Resistance of retinal ganglion cells to an increase in intraocular pressure is immune-dependent. Invest Ophthalmol Vis Sci 2002;43:2648-2653.
22. Fisher J, Levkovitch-Verbin H, Schori H, Yoles E, Butovsky O, Kaye JF, Ben-Nun A, Schwartz M. Vaccination for neuroprotection in the mouse optic nerve: Implications for optic neuropathies. J Neurosci 2001;21:136-142.
23. Hauben E, Agranov E, Gothilf A, Nevo U, Cohen A, Smirnov I, Steinman L, Schwartz M. Posttraumatic therapeutic vaccination with modified myelin self-antigen prevents complete paralysis while avoiding autoimmune disease. J Clin Invest 2001;108:591-599.
24. Kipnis J, Schwartz M. Dual action of glatiramer acetate (Cop-1) as a treatment for autoimmune diseases and a vaccine for protective autoimmunity after CNS injury. Trends Mol Med 2002;8:319-323.
25. Hafler DA. Degeneracy, as opposed to specificity, in immunotherapy. J Clin Invest 2002;109:581-584.
26. Angelov DN, Waibel S, Guntinas-Lichius O, Lenzen M, Neiss WF, Tomov TL, Yoles E, Kipnis J, Schori H, Reuter A, Ludolph A, Schwartz M. Therapeutic vaccine for acute and chronic motor neuron diseases: Implications for ALS. Proc Natl Acad Sci USA 2003;100:4790-4795.
27. Benner EJ, Mosley RL, Destache CJ, Lewis TB, Jackson-Lewis V, Gorantla S, Nemachek C, Green SR, Przedborski S, Gendelman HE. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc Natl Acad Sci USA 2004;101:9435-9440.
28. Bakalash S, Shlomo GB, Aloni E, Shaked I, Wheeler L, Ofri R, Schwartz M. T-cell-based vaccination for morphological and functional neuroprotection in a rat model of chronically elevated intraocular pressure. J Mol Med 2005;83:904-916.
29. Schori H, Yoles E, Wheeler LA, Raveh T, Kimchi A, Schwartz M. Immune-related mechanisms participating in resistance and susceptibility to glutamate toxicity. Eur J Neurosci 2002;16:557-564.
30. Schwartz M. Harnessing the immune system for neuroprotection: Therapeutic vaccines for acute and chronic neurodegenerative disorders. Cell Mol Neurobiol 2001;21:617-627.
31. Prendiville PL, McDonnell PJ. Complications of laser surgery. Int Ophthalmol Clin 1992;32:179-204.
32. Liu HF, Gao GH, Wu DC, Xu GD, Shi LS, Xu JM, Wang HB. Ocular injuries from accidental laser exposure. Health Phys 1989;56:711-716.
33. Dastgheib K, Bressler SB, Green WR. Clinicopathologic correlation of laser lesion expansion after treatment of choroidal neovascularization. Retina 1993;13:345-352.
34. Brancato R, Pece A, Avanza P, Radrizzani E. Photocoagulation scar expansion after laser therapy for choroidal neovascularization in degenerative myopia. Retina 1990;10:239-243.
35. Schatz H, Madeira D, McDonald HR, Johnson RN. Progressive enlargement of laser scars following grid laser photocoagulation for diffuse diabetic macular edema. Arch Ophthalmol 1991;109:1549-1551.
36. Morgan CM, Schatz H. Atrophic creep of the retinal pigment epithelium after focal macular photocoagulation. Ophthalmology 1989;96:96-103.
37. Ben-Shlomo G, Belokopytov M, Rosner M, Dubinsky G, Belkin M, Epstein Y, Ofri R. Functional deficits resulting from laser-induced damage in the rat retina. Lasers Surg Med 2006;38:689-694.
38. 25+ T cells. Eur J Immunol 2004;34:3434-3445.
39. Kipnis J, Nevo U, Panikashvili D, Alexandrovich A, Yoles E, Akselrod S, Shohami E, Schwartz M. Therapeutic vaccination for closed head injury. J Neurotrauma 2003;20:559-569.
40. Holm S. A simple sequentially rejective multiple test procedure. Scand J Statis 1979;6:65-70.
41. Belokopytov M, Dubinsky G, Belkin M, Epstein Y, Rosner M. Development and recovery of laser-induced retinal injury in rats. In: Manns F, Sderberg PG, Ho A, Stuck BE, Belkin M, eds. Ophthalmic Technologies XV. San Jose: SPIE; 2005. 312-319.
42. Rosner M, Solberg Y, Turetz J, Belkin M. Neuroprotective therapy for argon-laser induced retinal injury. Exp Eye Res 1997;65:485-495.
43. Maeshima K, Utsugi-Sutoh N, Otani T, Kishi S. Progressive enlargement of scattered photocoagulation scars in diabetic retinopathy. Retina 2004;24:507-511.
44. Schwartz M, Kipnis J. Protective autoimmunity and neuroprotection in inflammatory and noninflammatory neurodegenerative diseases. J Neurol Sci 2005;233:163-166.
45. Hauben E, Nevo U, Yoles E, Moalem G, Agranov E, Mor F, Akselrod S, Neeman M, Cohen IR, Schwartz M. Autoimmune T cells as potential neuroprotective therapy for spinal cord injury. Lancet 2000;355:286-287.
46. Hirschberg DL, Yoles E, Belkin M, Schwartz M. Inflammation after axonal injury has conflicting consequences for recovery of function: Rescue of spared axons is impaired but regeneration is supported. J Neuroimmunol 1994;50:9-16.
47. Schwartz M. Physiological approaches to neuroprotection, boosting of protective autoimmunity. Surv Ophthalmol 2001;45:S256-S260.
48. Schwartz M, Cohen IR. Autoimmunity can benefit self-maintenance. Immunol Today 2000;21:265-268.
49. Hirschberg DL, Moalem G, He J, Mor F, Cohen IR, Schwartz M. Accumulation of passively transferred primed T cells independently of their antigen specificity following central nervous system trauma. J Neuroimmunol 1998;89:88-96.
50. Moalem G, Gdalyahu A, Shani Y, Otten U, Lazarovici P, Cohen IR, Schwartz M. Production of neurotrophins by activated T cells: Implications for neuroprotective autoimmunity. J Autoimmun 2000;15:331-345.
51. Schori H, Yoles E, Schwartz M. T cell-based immunity counteracts the potential toxicity of glutamate in the central nervous system. J Neuroimmunol 2001;119:199-204.